Address: Via C. Colombo 1, I – 20020 Lainate,Italy
Tel: +39 02 9333 7614
Web: http://www.cosmopharmaceuticals.com/
Cosmo is a specialty pharmaceutical company that aims to become a global leader in the market of optimized therapies for selected gastro-intestinal diseases. The company’s proprietary clinical development pipeline specifically addresses innovative treatments for the gastro-intestinal tract, specifically Inflammatory Bowel Diseases (IBD), colon infections and colon diagnosis, as well as selected topically treated Skin Disorders.
Cosmo’s lead product Lialda®, the first product based on MultiMatrix Technology (‘MMX®’), was launched into the US market by Shire Pharmaceuticals plc on 19 March 2007. Another product, a nutraceutical, Zacol NMX®, is marketed in Italy and selected Eastern European countries. In addition the company has five pharmaceutical product candidates for the colon: Budesonide MMX® which has successfully completed phase III and has been filed for registration in the EU and US, Rifamycin SV MMX® which is in clinical phase III, LMW Heparin MMX® in phase II, Naloxon MMX®, which is in phase I and Blue Methylene MMX® which is in phase II. These products will address unmet needs in the diagnosis and treatment of colon diseases. This market is expected to grow, primarily because old and less effective products will be replaced by more effective ones. CB-03-01, the first new chemical entity the Company is developing is targeted at the acne, hirsutism and alopecia market and is presently in phase II.
Cosmo’s proprietary MMX® technology is at the core of the company’s product pipeline and was developed from its expertise in formulating and manufacturing gastro-intestinal pharmaceutical products for international clients at its GMP (Good Manufacturing Practice) facilities in Lainate, Italy.
Cosmo has a deep and broad expertise in the development of gastro-intestinal (GI) pharmaceutical products with a specific focus on Inflammatory Bowel Disease, based on the company’s innovative and proprietary MMX® technology. Most recently the Company has extended its expertise to other colon applications and to skin disorders where it is developing a new molecule.
The Company has built a successful and profitable pharmaceutical manufacturing business manufacturing products for international companies and in 2006 trebled its manufacturing capacity by adding a state-of-the-art, FDA-approved plant (for the production of Lialda®/Mezavant®), intended for the manufacturing of its own products.
The company’s proprietary MMX® technology is at the core of the product pipeline and was developed from its expertise in formulating and manufacturing GI pharmaceutical products for international clients. The research led to new patents that increased the efficacy of existing pharmaceutical products by modifying their formulations and tailoring their optimized delivery systems.
After long experience in the pharmaceutical industry, working in both multinational and local laboratories, you took the reins of the already well-established Italian subsidiary of Ferring a few months ago.…
Dr Fazi, you co-founded Eurogroup Consulting (EGC) in Italy in 2007 and are now leading a well established reality, renowned for the new model of governance it has designed. Could…
Following the successful result of the “Piano Sanitario Nazionale” 2005 – 2008, could you introduce to ours readers the key priorities and main health policies to be implemented by 2009…
Following 20 years of a comprehensive experience in diverse fields of the pharmaceutical industry, you entered Baxter in 2000. At the time, the Italian affiliate was already a well established…
Despite Italy being one of the most important pharmaceutical markets not only in Europe but also in the World, the industry remained quite stable for the last two years and…
Grunenthal-Formenti relies on Formenti’s 60 years experience in Italy and is the result of the merger of both the German and Italian entities in 96. How would you describe the…
Having led a 26 years long career in Pfizer, you have been involved in a number of different countries including leading markets such as the US and Japan, but also…
You have worked in other countries such as the UK and the US with very large and significant pharmaceutical industries. What would you say is particular about the Italian pharmaceutical…
Since 1982, CNR has been the Italian public body which most contributed to the creation of inventions and innovations. What have been the main strategies behind such a success in…
Over more than 25 years, PAREXEL has expanded its global footprint through a combination of organic growth, alliances, and acquisitions. What was the rationale behind entering Italy in 1995 and…
Roche Italy is one of the companies which went through the most significant re-organization process in the country in the past three years- with important changes in both its marketing…
When you were appointed General Director of the Agenzia Italiana del Farmaco (AIFA) in 2007, the dedicated Investigation Commission highlighted the need for an in-depth reorganization of the Agency in…
See our Cookie Privacy Policy Here
